Alto Neuroscience, Inc. Share Price & Technical Analysis
ANRO · $21.51 (+0.37%)
Healthcare / Biotechnology
$21.51
+0.37%
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinic…
Price chart
Seasonality
Jun has 1 positive and 2 negative years (last 3 years shown)
7% return in Jun, -14% avg return in past 3 year Jun month.
30% return in 2026, 89% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 29% | 16% | 14% | -21% | 7% | – | – | – | – | – | – | 30% |
| 25 | 0% | -33% | -37% | 14% | 4% | -15% | 41% | 23% | 8% | 255% | -2% | 32% | 289% |
| 24 | – | -30% | 0% | 1% | -22% | -12% | 2% | 21% | -12% | -66% | 13% | -5% | -111% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Uptrend
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$719.07M
P/E ratio
—
52W high
$28.44
52W low
$2.15
Volume
2,38,396
Beta
1.25
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Alto Neuroscience, Inc. share price today?
- Alto Neuroscience, Inc. (ANRO) last traded around $21.51 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ANRO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ANRO. Download the app for real-time alerts.
- How can I analyze Alto Neuroscience, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.